Stock Update: AbbVie Inc (NYSE:ABBV) – Europe gives green light to AbbVie hepatitis C medicine, others

[Reuters – UK Focus] – European regulators recommended approval for AbbVie’s hepatitis C drug dasabuvir, an experimental all-oral regimen for patients infected with the virus that could be an alternative to long courses . . . → Read More: Stock Update: AbbVie Inc (NYSE:ABBV) – Europe gives green light to AbbVie hepatitis C medicine, others Similar Articles: Market Update: AbbVie Inc (NYSE:ABBV) – ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty Market Update (NYSE:ABBV): AbbVie Reports Third-Quarter 2014 Financial Results Stock Update (NYSE:ABBV): AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C